about
Multiple sclerosis-a quiet revolutionRisk-benefit considerations in the treatment of relapsing-remitting multiple sclerosis.Current understanding on the role of standard and immunoproteasomes in inflammatory/immunological pathways of multiple sclerosis.Recombinant Antibody Fragments for Neurodegenerative Diseases.Human Tregs Made Antigen Specific by Gene Modification: The Power to Treat Autoimmunity and Antidrug Antibodies with PrecisionEpstein-barr virus in the central nervous system and cervical lymph node of a patient with primary progressive multiple sclerosis.
P2860
description
2013 nî lūn-bûn
@nan
2013 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
name
Humoral-targeted immunotherapies in multiple sclerosis
@ast
Humoral-targeted immunotherapies in multiple sclerosis
@en
Humoral-targeted immunotherapies in multiple sclerosis
@nl
type
label
Humoral-targeted immunotherapies in multiple sclerosis
@ast
Humoral-targeted immunotherapies in multiple sclerosis
@en
Humoral-targeted immunotherapies in multiple sclerosis
@nl
prefLabel
Humoral-targeted immunotherapies in multiple sclerosis
@ast
Humoral-targeted immunotherapies in multiple sclerosis
@en
Humoral-targeted immunotherapies in multiple sclerosis
@nl
P2860
P1433
P1476
Humoral-targeted immunotherapies in multiple sclerosis
@en
P2093
Sabeen Lulu
P2860
P2888
P356
10.1007/S13311-012-0164-3
P407
P577
2013-01-01T00:00:00Z
P6179
1051174698